Sunday, September 7, 2025
  • Hype
  • Murai
  • Lipstiq
  • Miss Murai
  • Varnam
  • Moviedash
  • Autofreaks
Lowyat.NET
  • News
    • Lifestyle
    • Computing
    • Hardware
    • Internet
    • Rumours & Leaks
    • Software
  • Forums
    • Kopitiam
    • Tradezone
    • Property Talk
    • Finance & Business
    • Fast and Furious
  • Gaming
    • PC Gaming
    • Console
    • Esports
  • Mobile
    • Apps
    • OS
    • Tablets
    • Phones
    • Telco
      • Celcom
      • DiGi
      • Maxis
      • Tune Talk
      • U Mobile
      • Buzzme
  • Pricelists
    • Compu-zoneUpdated
    • ViewnetUpdated
    • Sri ComputersUpdated
    • StartecUpdated
  • More
    • Automotive Tech
    • Drone
    • Enterprise
    • Entertainment
    • Fashion
    • E-Hailing
    • Wearables
No Result
View All Result
Lowyat.NET
  • News
    • Lifestyle
    • Computing
    • Hardware
    • Internet
    • Rumours & Leaks
    • Software
  • Forums
    • Kopitiam
    • Tradezone
    • Property Talk
    • Finance & Business
    • Fast and Furious
  • Gaming
    • PC Gaming
    • Console
    • Esports
  • Mobile
    • Apps
    • OS
    • Tablets
    • Phones
    • Telco
      • Celcom
      • DiGi
      • Maxis
      • Tune Talk
      • U Mobile
      • Buzzme
  • Pricelists
    • Compu-zoneUpdated
    • ViewnetUpdated
    • Sri ComputersUpdated
    • StartecUpdated
  • More
    • Automotive Tech
    • Drone
    • Enterprise
    • Entertainment
    • Fashion
    • E-Hailing
    • Wearables
No Result
View All Result
Lowyat.NET
No Result
View All Result
Home Coronavirus

Sarawak Is First To Acquire Ronapreve COVID-19 Treatment

It will only be available in Sarawak government hospitals for now.

by Ikmal Rozlan
December 23, 2021
sarawak Ronapreve covid-19

(Source: Dr Sim Kui Hian/Facebook)

246
SHARES
Share on FacebookShare on Twitter

Sarawak Local Government and Housing Minister Dr Sim Kui Hian has revealed that the state government has managed to acquire Ronapreve, a COVID-19 treatment made by US biotechnology company Regeneron and sold by Swiss pharmaceutical firm Roche.

Sarawak is the first state to make a deal with Roche since it was given conditional approval by the National Pharmaceutical Regulatory Agency (NPRA) on 13 December. Dr Sim said that the Ministry of Health (MoH) allowed the state government to acquire Ronapreve ahead of the federal government, which has yet to purchase the medicine for other states, to be used in government hospitals in Sarawak.

regeneron
[Photo: Regeneron]

Ronapreve is a monoclonal antibody cocktail made up of two drugs — casirivimab and imdevimab. It is administered through an injection and has been found to reduce the risk of death or hospitalisation by 70%. The combination is approved for medical use in Japan, the United Kingdom, the European Union, and Australia, and was famously used to treat then-US President Donald Trump in 2020 when he was infected with the virus.

According to Dr Sim, the treatment will be given to COVID-19 patients with severe symptoms in Category Four, although Health director-general Dr Noor Hisham previously said that it’s approval is for use on those who don’t require supplemental oxygen and are at risk of progressing to severe disease.

vaccine vaccination injection
[Photo: ronstik/Pixabay]

Dr Sim did not reveal the exact price tag of the procurement, but said that it costs thousands per dose. On that note, Japan recently bought 500,000 doses at a cost of 310,000 Japanese Yen (~RM11,400) per dose.

ALSO READ:  Sarawak To Provide Teachers With Specialised AI Training

Meanwhile, MoH revealed plans to acquire several COVID-19 drugs prior to this. These include the molnupiravir antiviral pill as well as treatments being developed by Pfizer and AstraZeneca.

(Source: Dr Sim Kui Hian/Facebook)

Filed Under COVID-19RonapreveSarawak
Updated 5:43 pm, Thu, 23 December 21
http://lowy.at/hpFO8
Share98Tweet62SendShare

Follow us on Instagram, Facebook, Twitter or Telegram for more updates and breaking news. 

No Result
View All Result

TRENDING THIS WEEK

  1. 1
    Transportation

    East Klang Valley Expressway (EKVE) Opens; Toll-Free Travel Until 29 September 2025

  2. 2
    Automotive

    BYD Teases New EV For Malaysian Market

  3. 3
    News

    Xiaomi Recalls 33W Power Bank 20,000mAh In Malaysia

  4. 4
    Hardware

    Microsoft Says SSD Failures Not Linked To Windows Updates

  5. 5
    Mobile Phones

    Sony Explains Manufacturing Issues Of The Xperia 1 VII

NETWORK

  • Hype
  • Murai
  • Lipstiq
  • Miss Murai
  • Varnam
  • Moviedash
  • Autofreaks

ABOUT

  • Advertise
  • Careers
  • Privacy Statement
  • Contact Us
  • Editorial Policy
  • Terms & Conditions

©2025 VIJANDREN RAMADASS. ALL RIGHTS RESERVED.

No Result
View All Result
  • News
    • Lifestyle
    • Computing
    • Hardware
    • Internet
    • Rumours & Leaks
    • Software
  • Forums
    • Kopitiam
    • Tradezone
    • Property Talk
    • Finance & Business
    • Fast and Furious
  • Gaming
    • PC Gaming
    • Console
    • Esports
  • Mobile
    • Apps
    • OS
    • Tablets
    • Phones
    • Telco
      • Celcom
      • DiGi
      • Maxis
      • Tune Talk
      • U Mobile
      • Buzzme
  • Pricelists
    • Compu-zone
    • Viewnet
    • Sri Computers
    • Startec
  • More
    • Automotive Tech
    • Drone
    • Enterprise
    • Entertainment
    • Fashion
    • E-Hailing
    • Wearables

©2025 VIJANDREN RAMADASS. ALL RIGHTS RESERVED.

No Result
View All Result
  • News
    • Lifestyle
    • Computing
    • Hardware
    • Internet
    • Rumours & Leaks
    • Software
  • Forums
    • Kopitiam
    • Tradezone
    • Property Talk
    • Finance & Business
    • Fast and Furious
  • Gaming
    • PC Gaming
    • Console
    • Esports
  • Mobile
    • Apps
    • OS
    • Tablets
    • Phones
    • Telco
      • Celcom
      • DiGi
      • Maxis
      • Tune Talk
      • U Mobile
      • Buzzme
  • Pricelists
    • Compu-zone
    • Viewnet
    • Sri Computers
    • Startec
  • More
    • Automotive Tech
    • Drone
    • Enterprise
    • Entertainment
    • Fashion
    • E-Hailing
    • Wearables

©2025 VIJANDREN RAMADASS. ALL RIGHTS RESERVED.